Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CSL ( (AU:CSL) ).
CSL Limited has scheduled the release of its 2026 half-year financial results for Wednesday, 11 February 2026, underscoring its regular reporting cadence to the market. The company will brief investors and analysts via a webcasted presentation at 10:00am AEDT that day, with results materials and a recording to be made available through the investor section of its website, providing stakeholders with detailed access to the group’s interim performance and outlook.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$199.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a Melbourne-based global biotechnology company listed on the ASX and US OTC markets, best known for its plasma-derived therapies, vaccines and other biopharmaceutical products serving patients and healthcare systems worldwide.
YTD Price Performance: 5.08%
Average Trading Volume: 923,539
Technical Sentiment Signal: Sell
Current Market Cap: A$88.02B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.